RedHill Biopharma (RDHL) Non Operating Income (2012 - 2023)

RedHill Biopharma (RDHL) has reported Non Operating Income for 12 consecutive years, with $47.5 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non Operating Income rose 1760.93% year-over-year to $47.5 million in Q2 2023; TTM through Jun 2023 was -$8.9 million, a 53.17% increase from a year earlier, with the FY2025 full-year figure at -$138000.0, down 102.02% from the prior year.
• Non Operating Income was $47.5 million for Q2 2023 at RedHill Biopharma, up from -$21.2 million in the prior quarter.
• Over five years, Non Operating Income peaked at $47.5 million in Q2 2023 and troughed at -$63.9 million in Q4 2022.
• A 5-year average of -$397200.0 and a median of $3.9 million in 2022 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 3241.13% in 2021, down 739.07% in 2021.
• Over 5 years, Non Operating Income stood at $657000.0 in 2019, then jumped by 603.65% to $4.6 million in 2020, then tumbled by 739.07% to -$29.5 million in 2021, then tumbled by 116.18% to -$63.9 million in 2022, then surged by 174.36% to $47.5 million in 2023.
• The last three Non Operating Income figures came in at $47.5 million (Q2 2023), -$21.2 million (Q1 2023), and -$63.9 million (Q4 2022), per Business Quant data.